Your browser doesn't support javascript.
loading
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
Ladewig, Erik; Michelini, Flavia; Jhaveri, Komal; Castel, Pau; Carmona, Javier; Fairchild, Lauren; Zuniga, Adler G; Arruabarrena-Aristorena, Amaia; Cocco, Emiliano; Blawski, Ryan; Kittane, Srushti; Zhang, Yuhan; Sallaku, Mirna; Baldino, Laura; Hristidis, Vasilis; Chandarlapaty, Sarat; Abdel-Wahab, Omar; Leslie, Christina; Scaltriti, Maurizio; Toska, Eneda.
Afiliação
  • Ladewig E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Michelini F; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jhaveri K; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Castel P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Carmona J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Fairchild L; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York.
  • Zuniga AG; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Arruabarrena-Aristorena A; Weill Cornell Medical College, New York, New York.
  • Cocco E; Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York.
  • Blawski R; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Baltimore, Maryland.
  • Kittane S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Zhang Y; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.
  • Sallaku M; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
  • Baldino L; Translational prostate cancer Research lab, CIC bioGUNE-Basurto, Biocruces Bizkaia Health Research Institute, Derio, Spain.
  • Hristidis V; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chandarlapaty S; Department of Biochemistry and Molecular Biology, University of Miami, Miller School of Medicine, Miami, Florida.
  • Abdel-Wahab O; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Baltimore, Maryland.
  • Leslie C; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, Maryland.
  • Scaltriti M; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, Maryland.
  • Toska E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Res ; 82(12): 2269-2280, 2022 06 15.
Article em En | MEDLINE | ID: mdl-35442400
ABSTRACT
The phosphoinositide 3-kinase (PI3K) pathway regulates proliferation, survival, and metabolism and is frequently activated across human cancers. A comprehensive elucidation of how this signaling pathway controls transcriptional and cotranscriptional processes could provide new insights into the key functions of PI3K signaling in cancer. Here, we undertook a transcriptomic approach to investigate genome-wide gene expression and transcription factor activity changes, as well as splicing and isoform usage dynamics, downstream of PI3K. These analyses uncovered widespread alternatively spliced isoforms linked to proliferation, metabolism, and splicing in PIK3CA-mutant cells, which were reversed by inhibition of PI3Kα. Analysis of paired tumor biopsies from patients with PIK3CA-mutated breast cancer undergoing treatment with PI3Kα inhibitors identified widespread splicing alterations that affect specific isoforms in common with the preclinical models, and these alterations, namely PTK2/FRNK and AFMID isoforms, were validated as functional drivers of cancer cell growth or migration. Mechanistically, isoform-specific splicing factors mediated PI3K-dependent RNA splicing. Treatment with splicing inhibitors rendered breast cancer cells more sensitive to the PI3Kα inhibitor alpelisib, resulting in greater growth inhibition than alpelisib alone. This study provides the first comprehensive analysis of widespread splicing alterations driven by oncogenic PI3K in breast cancer. The atlas of PI3K-mediated splicing programs establishes a key role for the PI3K pathway in regulating splicing, opening new avenues for exploiting PI3K signaling as a therapeutic vulnerability in breast cancer.

SIGNIFICANCE:

Transcriptomic analysis reveals a key role for the PI3K pathway in regulating RNA splicing, uncovering new mechanisms by which PI3K regulates proliferation and metabolism in breast cancer. See related commentary by Claridge and Hopkins, p. 2216.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fosfatidilinositol 3-Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fosfatidilinositol 3-Quinases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article